Navigation Links
Widespread support for rapid HIV testing in dental surgeries -- new study
Date:7/15/2014

More than 80 per cent of oral health patients are willing to receive rapid HIV-testing in dental settings, which could help reduce the spread of the HIV according to a groundbreaking study revealed today at a Sydney University HIV Testing Symposium.

The first of its kind study of 521 Sydney-based dental patients assessed patients' willingness to undergo rapid HIV testing in dental settings, their preference for HIV testing-type type and their willingness to pay for the test.

Rapid HIV testing is a screening test that swiftly detects the presence of HIV antibodies in a person's body by testing blood or oral fluids.

It can be done as a simple finger prick or a saliva swab, and results can be made available within 20 minutes.

Rapid HIV testing is currently unavailable in dental settings anywhere in the world although the technology has been widely available for a decade.

Australians will soon be able to access rapid HIV-testing themselves after the federal government last week announced that it had lifted restrictions preventing the manufacture and sale of oral home-testing kits.

"Dentists are well placed to offer rapid HIV testing because they're located throughout the community, have ongoing relationships with their patients, and have the necessary training and expertise to recognise systemic diseases that have oral manifestations, such as HIV/AIDS," says the study's lead author, Dr Anthony Santella of the University of Sydney.

The new research finding has important policy implications, according to Dr Santella: "If rapid HIV testing was widely available in dental settings it could help to reduce the spread of the virus by informing people who aren't aware that they are HIV-positive.

"It's important that policymakers and other stakeholders consider expanding rapid HIV testing beyond medical and sexual health clinics because the average time from HIV infection to diagnosis in Australia is currently more than three years."

"As well, we have fresh evidence that around 45 per cent of dentists feel prepared and willing to perform rapid HIV-testing. This means it would be feasible to offer rapid HIV testing through dental settings, especially in targeted at risk communities."

Among those saying they'd be willing to undergo rapid HIV testing in a dental setting, 76 per cent preferred an oral saliva swab, 15 per cent preferred a pin prick test, and eight per cent preferred a traditional blood test that draws blood through a needle.


'/>"/>

Contact: Dan Gaffney
daniel.gaffney@sydney.edu.au
61-481-004-782
University of Sydney
Source:Eurekalert

Related biology news :

1. Targeting tuberculosis hotspots could have widespread benefit
2. Wrinkled surfaces could have widespread applications
3. Study: Widespread test-and-treat HIV policies could increase dangerous drug resistance
4. Huge and widespread volcanic eruptions triggered the end-Triassic extinction
5. Notre Dame study finds Asian carp DNA not widespread in the Great Lakes
6. Asian carp DNA not widespread in the Great Lakes
7. Climate change will cause widespread global-scale loss of common plants and animals
8. Widespread but neglected disease a health threat in Africa, Virginia Tech researchers say
9. Toxic methylmercury-producing microbes more widespread than realized
10. The most widespread ant and its new relative: A revision of the genus Paratrechina
11. MERS virus widespread in Saudi Arabian camels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... WEST PALM BEACH, Fla. , Feb. 16, ... molecular diagnostics company revolutionizing the development of liquid ... that it has entered into an exclusive license ... who will distribute MDNA,s proprietary liquid biopsy test ... in South Korea . This ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
Breaking Biology Technology: